Study COVID-19 variants
Reagents?- Three fast-spreading new variants of SARS-CoV-2 virus have emerged in recent months: the U.K. variant B.1.1.7, the Brazil variant P.1, and the South Africa variant B.1.351.
A subset of the mutations identified in the RBD domain of the spike protein occurs in more than one strain, although the three variants are believed to be independently evolved. These convergent mutations, specifically, the N501Y (shared by all three, 40592-V08H82) and E484K (shared between B.1.351 and P.1, 40592-V08H84), are of high interest because they may be the cause of the increased transmissibility.
The mutations in these strains also occur in the nucleocapsid protein, which is commonly used as the biomarker in rapid antigen tests. Its critical to assess whether the current commercial antigen tests can detect the mutated N proteins with the same sensitivity and specificity as their WT counterpart.
Sino Biological has developed 80+ recombinant RBD/Spike and Nucleocapsid protein mutants carrying the aforementioned mutations, which can be used to evaluate the efficacy of the antibodies and vaccination.
Contact
Sino Biological Europe GmbH
order_eu@sinobiological.com
Sino Biological Inc.
marketing@sinobiological.com
www.sinobiological.com/
Certest
Consilium